Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
37.00
-0.24 (-0.64%)
Mar 4, 2026, 12:59 PM EST - Market open
Cogent Biosciences Stock Forecast
Stock Price Forecast
The 14 analysts that cover Cogent Biosciences stock have a consensus rating of "Buy" and an average price target of $33.5, which forecasts a -9.46% decrease in the stock price over the next year. The lowest target is $9.00 and the highest is $67.
Price Target: $33.5 (-9.46%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cogent Biosciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 3 | 3 | 3 | 3 | 4 | 5 |
| Hold | 2 | 3 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 13 | 13 | 14 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $39 → $52 | Buy | Maintains | $39 → $52 | +40.54% | Feb 18, 2026 |
| Wedbush | Wedbush | Buy Reiterates $55 | Buy | Reiterates | $55 | +48.65% | Jan 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $52 | Strong Buy | Maintains | $50 → $52 | +40.54% | Jan 6, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $65 → $67 | Buy | Maintains | $65 → $67 | +81.08% | Dec 19, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Dec 8, 2025 |
Financial Forecast
Revenue This Year
47.70M
Revenue Next Year
289.34M
from 47.70M
Increased by 506.58%
EPS This Year
-1.87
from -2.55
EPS Next Year
-0.26
from -1.87
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 166.6M | 489.8M | |||
| Avg | 47.7M | 289.3M | |||
| Low | n/a | 114.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 926.9% | |||
| Avg | - | 506.6% | |||
| Low | - | 140.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.35 | 2.68 | |||
| Avg | -1.87 | -0.26 | |||
| Low | -2.29 | -1.36 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.